Allogeneic CD8 + cytotoxic T cells play an essential role in rejecting transplanted allografts, but how their effector function is regulated on a transcriptional level remains unclear. Herein, we investigate the role of interferon regulatory factor 4 (IRF4) in controlling CD8 + T-cell function in response to transplant. B6.Rag1 À/À mice were adoptively transferred with CD8 + T cells isolated from either Irf4 fl/fl Cd4-Cre (T-cell-specific Irf4deficient) or Irf4 fl/fl control mice, followed by BALB/c skin transplantation. Recipients that received Irf4-deficient CD8 + T cells permanently accepted the skin allografts, whereas recipients that received control CD8 + T cells acutely rejected the transplanted skins. Mechanistically, compared with the transferred control CD8 + T cells in B6.Rag1 À/À recipients, the transferred Irf4-deficient CD8 + T cells lost the capacity to differentiate into CD127 À KLRG1 + terminal effector cells, barely produced effector cytokines and cytotoxic molecules (e.g. IL-2, IFN-c, TNF-a, granzyme A and granzyme B), and displayed defect in proliferative capacity, evident by their decreased Ki67 expression and lower frequencies. Moreover, the transferred Irf4-deficient CD8 + T cells displayed low expression of transcription factors ID2 and T-bet that govern the terminal effector T-cell programmes, and high expression of transcription factor TCF1 that maintains the na€ ıve-memory T-cell programmes. Hence, IRF4 deficiency in CD8 + T cells abrogates their terminal effector differentiation and promotes transplant acceptance. These findings suggest that targeting IRF4 expression represents an attractive and promising therapeutic approach for inducing transplant acceptance.